NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription

Xiaobin Zao*, Jin Cheng*, Congle Shen, Guowen Guan, Xiaoyu Feng, Jun Zou, Jing Zhang, Tianxu Liu, Huiling Zheng, Ting Zhang, Jie Wang, Jia Liu, Deyao Li, Fengmin Lu, Fuping You, and Xiangmei Chen

*Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, China; †Department of Sports Medicine, Peking University Third Hospital, Institute of Sports Medicine of Peking University, Beijing Key Laboratory of Sports Injuries, Beijing, China; ‡Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China; †Institute of Systems Biomedicine, Department of Immunology, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China

ABSTRACT
Nuclear factor of activated T cells 3 (NFATc3) has been reported to upregulate type I interferons (IFNs) expression, and the abnormal expression and activation of NFATc3 were closely related to tumorigenesis. However, the potential function of NFATc3 in hepatitis B virus (HBV)-related hepatocarcinoma (HCC) remains to be elucidated. In this study, we found that NFATc3 gene was frequently deleted and downregulated in HCC tumor tissues, and that the downregulation of NFATc3 was associated with poor prognosis of HCC patients. The gain- and loss-of-function experiments demonstrated that NFATc3 inhibited HCC cell proliferation and invasion, as well as HBV replication. Mechanistically, NFATc3 could bind to the promoters of IFNL1 and IFNB1 genes and prompt the production of IFNs and interferon-stimulated genes. Furthermore, retinoic acid-inducible gene-I (RIG-I) pathway activation increased NFATc3 expression and nuclear localization, and activated NFATc3 further enhanced RIG-I-mediated IFN responses. Collectively, our findings reveal a novel regulatory signaling cascade, the RIG-I/NFATc3/IFNs axis, which inhibits hepatocarcinogenesis and HBV replication by enhancing the immune response in hepatocytes, and this functional axis might potentially be exploited for therapeutic benefits in the clinical treatment of HBV-related HCC.

1. Introduction
Chronic hepatitis B caused by hepatitis B virus (HBV) infection is the leading cause of cirrhosis and hepatocellular carcinoma (HCC). Despite the existence of effective prophylactic vaccine, approximately 257 million people worldwide are living with chronic HBV infection and high risk of developing cirrhosis and HCC. It is recognized that accumulation of genetic damage due to immune-mediated hepat inflammation was involved in HCC development. However, the complex and multifactorial pathogenic mechanisms underlying the development of HBV-related HCC are still poorly understood.

The nuclear factor of activated T cells (NFAT) family is a group of calcium/calcineurin-dependent transcription factors which is originally identified as mediators for activation of cytokine genes in T cells during immune response. More than three decades after the discovery, the NFAT proteins are found to be expressed in many kinds of cells other than immune cells and play critical roles during and after embryonic development, including inflammatory response, cardiac valve formation, myocardial development and other biological processes. The NFAT family has four typical members, including NFATc1, NFATc2, NFATc3 and NFATc4. Accumulating evidences has indicated that the abnormal expression of NFAT proteins was involved in the development and progression of cancers. However, different NFAT proteins appeared to have distinct roles in the development of cancers.

NFATc3 is a member of NFAT family which has been shown to have either pro-tumor or anti-tumor effects, depending on the physiologic and cellular context. For example, T cell lymphoma and breast cancer were more frequently observed in NFATc3 deficient mice, which suggested that NFATc3 appeared to have anti-tumor potential in these two cancers. While in oral/oropharyngeal squamous cell carcinomas, NFATc3 expression and activation promoted tumor development. However, the expression status and function of NFATc3 in hepatocarcinogenesis remain largely unknown. The human interferon (IFN) response is a key innate immune mechanism to fight virus infection and tumor development. IFNs are a group of signaling proteins released by host cells in response to the presence of viruses, bacteria, parasites and tumor cells. After binding to receptors, IFNs activate...
downstream JAK-STAT pathways and induce hundreds of interferon-stimulated genes (ISGs) to exert anti-tumor and anti-virus function. Among IFNs, type I IFNs are representative cytokines of host innate immune response, which have been used in clinical treatment for HBV infection and HCC. Type III IFNs (also called IFN-λ) are predominantly expressed in hepatocytes which also exert significant anti-viral activity and extensive anti-tumor function in various types of cancers including HCC. Recently, NFATc3 has been found to positively regulate type I IFNs production and enhance interferon regulate factor 7 (IRF7)-mediated IFN response in plasmacytoid dendritic cells (pDCs), while in hepatocytes, IRF7 is mainly involved in retinoic acid-inducible gene-1 (RIG-I)/mitochondrial antiviral protein (MAVS) pathway. In hepatocytes, whether NFATc3 plays a role in RIG-I/MAVS-mediated innate immunity and regulates the expression of IFNs, especially IFN-λs, remains to be elucidated.

In the present study, we aim to explore the role of NFATc3 in the regulation of HBV replication and HCC development. We found that NFATc3 expression was downregulated in HCC tissues caused by gene copy deletion. Interestingly, we identified that NFATc3 functions as a downstream transcription factor of RIG-I-MAVS-IRF7 pathway to upregulate IFNL1 and IFNB1 expression in hepatocytes, thereby inhibiting oncogenic properties of HCC cells as well as HBV replication. Thus, our findings provide new insights into the function and mechanism of NFATc3 in hepatocarcinogenesis.

2. Materials and methods

2.1. Clinical samples and patient information.

Seventy-five pairs of frozen HCC samples were collected from the Affiliated Cancer Hospital of Zhengzhou University from 2009 to 2012. All HCC tissues were histopathologically confirmed with primary HCC criteria and showed cirrhosis of varying degrees. All cases were hepatitis B surface antigen (HBsAg) positive, with elevated or normal levels of alanine aminotransferase (ALT), and ranged in age from 28 to 75 years old. The clinicopathological characteristics of patients including gender, age, Barcelona Clinic Liver Cancer (BCLC) stage, tumor size and number, capsule, intrahepatic metastasis, portal venous thrombus, and alpha-fetoprotein (AFP) levels were shown in Supplementary Table S1. Seven normal liver tissues were obtained from healthy liver donors. The study protocol was approved by the Ethics Committee of Peking University Health Science Center. Informed consent was obtained from each participant.

2.2. Databases

The gene sequence information was obtained from National Center for Biotechnology Information (NCBI) database (https://www.ncbi.nlm.nih.gov/). The Cancer Genome Atlas (TCGA) data were downloaded from MEXPRESS (https://mexpress.be) and cBioPortal for Cancer Genomics (http://www.cbioportal.org/) websites for further analysis. The genomic profiles included DNA methylation, copy-number alteration (CNA) and mutation from GISTIC and mRNA expression z-scores (RNA Seq V2 RSEM). The GSE83148 data were downloaded from Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/). The prognostic value of gene mRNA expression in TCGA was evaluated using an online database, Kaplan-Meier Plotter (www.kmplot.com). To analyze the overall survival (OS) of HCC patients, samples were split into two groups by best cutoff (high vs. low expression) and assessed by a Kaplan-Meier survival plot, with the hazard ratio (HR) of 95% confidence intervals (CI) and log-rank p value.

2.3. Cell lines

HEK293T, Hep3B, SMMC7721, SNU449, SK-Hep1, Huh7, HepG2 and 2fTGH cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 5% CO2. For HepAD38 cells, the media were additionally supplemented with 400 µg/mL G418 sulfate (InvivoGen). HEK293T, Hep3B, SNU449, SK-Hep1, Huh7 and HepG2 cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Human HCC cell line SMMC7721 was purchased from Cell Resources Center of Peking Union Medical College (Beijing, P. R. China), and the origin of SMMC7721 has been proved with STR, hepatic gene expression and specific gene mutations. 2fTGH-ISRE cells were provided by Professor Fuping You (Peking University, Beijing, China).

2.4. Plasmids and transfection

HBV expression plasmids contains 1.2 × C type HBV genome was constructed with pBlueBac4.5 vector which can only replicate in prokaryotic cells. The prcccDNA and pCMV-Cre plasmids were gifts from Professor Qiang Deng (Fudan University, Shanghai, China). NFATc3 cDNA clone (Origene) was constructed into pcDNA3.1/V5-His vector, which can express wild-type NFATc3 protein with His-tag in C terminal. NFATc3 cDNA clone was also constructed into pLEX-MCS vector, which can express NFATc3 wild-type protein with Flag-tag in C terminal. Luciferase plasmids containing IFNB1 promoter and interferon-stimulated response element (ISRE), constructed into PGL3-basic vector, were gifts from Professor Jianhua Yang (Baylor College of Medicine, Houston, TX, USA). IFN1 promoter (region: −986 to −1) was cloned into pGL3-Basic vector (Promega, US). NFATc3 binding sites on IFNB1 and IFN1 promoters were mutated by the site-directed mutagenesis method (Takara, PrimerSTAR Max DNA Polymerase, Japan) with the constructs encoding wild-type IFNB1-Luc and IFN1-Luc as the template. Expressing plasmids of IRF3, IRF7 and MAVS were gifts from Professor Fuping You (Peking University, Beijing, China). All vectors were transfected into cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA).

2.5. Sendai virus infection

The Sendai virus (SeV) was provided by Professor Fuping You and kept at −80°C. After thawing, the virus was added
into the cultural supernatant, and cells were harvested after 24–36 hours.

2.6. IFN pathway blocking

Recombinant orthopoxviral immunomodulatory proteins (B18R, Ebioscience, US) were added into the cultural supernatant with a final concentration of 200 ng/mL, the supernatant and cells were harvested after 24–120 hours.

2.7. CCK-8 assay

A total of 1 × 10^4 cells were seeded in 96-well plates with six duplications, and then CCK-8 assay (Beyotime, CN) was carried out to assess cell viability through measuring the absorbance at the wavelength of 450 nm by the TECAN infinite M200 Multimode microplate reader (Tecan, Mechelen, Belgium).

2.8. Transwell assay

Transwell assay was conducted to measure the ability of cell migration. Around 100 μL serum-free medium containing cells (1 × 10^6 cells/mL) were planted into the upper chamber with a pore size of 8 μm (Corning, Corning, NY, US), meanwhile, 800 μL medium containing 10% FBS was added in the lower chamber. After 48 hours, migrated cells were fixed with paraformaldehyde and stained with crystal violet (Beyotime, CN), then counted with Image-pro Plus 6.0 software under 40× magnification (five views per well). The experiments were performed in triplicate and repeated 3 times.

2.9. Wound healing assay

Cells were seeded in the 6-well plates. After 12 hours, the cell monolayer was scratched with a sterile 10 μL pipette tip to generate a line-shaped wound. Then the cells were cultured in DMEM without FBS. Forty-eight hours later, images of the scratches were acquired with a digital camera. The scratch areas were quantified using Image-pro Plus 6.0 software. The experiments were performed in triplicate and repeated 3 times.

2.10. Dual luciferase reporter assay

Cells were seeded in 24-well plates, then transfected with the IFN1-Luc or IFNL1-Luc plasmids together with pRL-TK renilla vector (Promega, US). Thirty-six hours after transfection, cells were lysed and luciferase activity was detected with a dual-luciferase reporter assay kit (Promega, US). The two fTGH-ISRE luciferase assay was performed as previously described.25 The experiments were performed in triplicate and repeated 3 times.

2.11. Quantitative real-time PCR

Total RNAs were extracted from the cells or tissues using TRIzol® Reagent according to the manufacturer’s instructions (Invitrogen) and genomic DNA was removed using DNase I (TaKara). The reverse transcription of total RNA to cDNA was performed with Thermo RT supermix kit. Quantitative Real-time PCR (qRT-PCR) was performed using the ABI StepOnePlus Real-time PCR Detection System (Applied Biosystems, US) with an SYBR green fluorescence system. The primers used in this study are provided in Supplementary Table S3, using CTBP as internal control gene for hepatoma cells and GAPDH for HEK293T. The experiments were performed in triplicate and repeated 3 times.

2.12. RNA-sequencing and data analysis

SeV-infected WT and NFATc3-KO SMMC7721 cells were sent to Majorbio-Tech for sequencing. The transcriptome library was prepared following TruSeqTM RNA sample preparation Kit from Illumina (San Diego, CA) using 1 μg of total RNA. Firstly, messenger RNA was isolated according to polyA selection method by oligo (dT) beads and then fragmented by fragmentation buffer firstly. Secondly, double-stranded cDNA was synthesized using a SuperScript double-stranded cDNA synthesis kit (Invitrogen, CA) with random hexamer primers (Illumina). Then the synthesized cDNA was subjected to end-repair, phosphorylation and ‘A’ base addition according to Illumina’s library construction protocol. Libraries were size selected for cDNA target fragments of 200–300 bp on 2% Low Range Ultra Agarose followed by PCR amplified using Phusion DNA polymerase (NEB) for 15 PCR cycles. After quantified by TBS380, paired-end RNA-seq sequencing library was sequenced with the Illumina HiSeq xten/NovaSeq 6000 sequencer (2 × 150 bp read length), and the data were analyzed on the free online platform of Majorbio Cloud Platform (www.majorbio.com).

2.13. Methylation-specific restrictive enzyme-based quantitative PCR (MSRE-qPCR)

MSRE-qPCR was performed as described,29 and designed primers were as follows:

- NFATc3 methy forward: 5'-AGGCCCTGCCCATTGGGGTTCGCT-3';
- NFATc3 methy reverse: 5'-TTGCCCCAGTGGCCTGCGCCT-3'.

2.14. CRISPR/Cas9 strategy

SMMC7721 cells were transduced with double Px458-Cas9 plasmids containing guide RNA targeting NFATc3 gene, and then Cas9 expressing cells were selected and clonal expanded. The knockout efficiency was determined by immunoblotting. The sequences of the two guide RNA targeting NFATc3 gene were as follows:

First (sense), 5’-CCGATGACTACTGCAAACTG-3';
Second (sense), 5’-CGCCGCCGCCCCCGGGGCTCG-3'.

2.15. Chromatin immunoprecipitation assay

HEK293T cells were fixed, lysed, and sonicated. Precleared lysates were incubated overnight at 4°C with mouse anti-Flag antibody, or control mouse IgG. Immunocomplex was
collected, purified, and analyzed by Real-time PCR. Primers
used for ChIP-PCR were as followed:
IFNB1: Forward: 5’-ggctctgactttcaggtcg-3’; Reverse: 5’-
ccccctcttacttcctctcc-3’;
IFNL1: Forward: 5’-ctctcttgatgcagctccca-3’; Reverse: 5’-
cagcgaatgggcaatc-3’.

2.16. Nuclear-cytoplasmic protein fractionation and western blotting
Cells were seeded in 60 mm dishes, and nuclear-cytoplasmic
fractionation was conducted using the lysis buffers of NEPER
Nuclear and Cytoplasmic Extraction Reagents kit (Thermo
Fisher Scientific, US) according to the manufacturer’s protocol,
supplemented with protease inhibitor cocktail (Roche). The
protein lysates were separated by 10% sodium dodecyl sulfates
polyacrylamide gel and then electrophoretically transferred
(Bio-Rad) onto the PVDF membrane (Amersham Biosciences,
Uppsala, Sweden). After blocking, membranes were
incubated with the relevant primary antibodies at 4°C
overnight, and then incubated with the secondary antibodies
at room temperature for 1 hour. LaminB1 was used as internal
control protein for nucleus, GAPDH, α-Tublin and β-Actin for
cytoplasm or total. Band signals were visualized by Odyssey
Imager (LI-COR Biosciences, Lincoln, NE). The antibodies
used for immunoblot and/or immunoprecipitation assays
were provided in Supplementary Table S4.

2.17. Tumor xenograft assay
A total of 2.5 × 10⁶ WT and NFATc3-KO SMMC7721 cells
were injected into underarm skin on each side of the same
nude mouse simultaneously (6-week old, female), then the
mice were monitored for tumor forming every 3 days, tumor
dimensions were measured twice a week and tumor volume
was calculated using Volume = π/6×(length)×(width)². After
eight weeks, the mice were sacrificed and tumors were obtained
for measuring the sizes and weights of tumors. All experiments
in mice were conducted according to institutional guidelines of
Peking University Health Science Center.

2.18. Hydrodynamic injection (HDI)
The hydrodynamic injection was performed as previously
described. Briefly, 16 μg plasmids were injected into the tail
vein of C57BL/6 mice (6-week old, male) in 2 mL PBS (almost
equivalent to 8% of the mouse body weight) within 5 seconds.
Then sera were collected at 3, 5 and 7th days post-injection.
C57BL/6 mice were purchased from the Department of
Laboratory Animal Science, Peking University Health Science
Center. Animals were housed in specific pathogen-free barrier
facilities. All experiments in mice were conducted according to
institutional guidelines of Peking University Health Science
Center.

2.19. Detection of HBV DNA
The HBV DNA in the cell culture medium and sera of mice
were extracted using the EasyPure Viral DNA Kit (TransGen
Biotech, CN) according to the manufacturer’s instructions.
Then the HBV DNA was detected by qPCR assay. The serial
dilutions of pBB4.5–1.2× HBV plasmid were used as standards of
quantification. The experiments were performed in triplicate and
repeated 3 times.

2.20. Detection of HBsAg and HBeAg
The levels of HBsAg and HBeAg in the cell culture supernatant
or mouse sera were measured in triplicate by the diagnostic kit
for the quantitative determination of HBsAg or HBeAg (time-
resolved Immunofluorometric Assay) (PerkinElmer, Waltham,
MA, USA) following the manufacturer’s instructions.

2.21. Statistical analysis
For all the bar graphs, data were presented as means ± SD.
GraphPad Prism software, version 7.00 for Windows
(GraphPad Software, Inc., La Jolla, CA), was used for survival
curves, charts, and statistical analysis. For the comparison of
quantitative data between groups, the Student’s t-test was used,
otherwise, independent sample rank sum test was used; survi-
val was calculated using Kaplan-Meier’s method and compared
using log-rank test; Spearman rank correlation test was used to
calculate the correlation between two nonparametric values.
Differences in means were considered statistically significant at
P < .05. Significance levels are: *, P < .05; **, P < .01; ***,
P < .001; ****, P < .0001; ns, not significant.

3. Results
3.1. NFATc3 expression is downregulated in HCC tissues
due to gene deletion
Based on the data from The Cancer Genome Atlas (TCGA), we
investigated the expression of NFATc3 in HCC. The results
showed that NFATc3 expression was downregulated in HCC
tissues (Figure 1a) and the lower NFATc3 expression was
significantly correlated with the poor 5-year overall survival
(OS) in patients with HCC (n = 343, P= .048) (Figure 1b).
Consistently, we confirmed that the mRNA level of NFATc3 in
tumor tissues was significantly lower than that in paired para-
tumor tissues, and both were significantly lower than that in
normal liver tissues in our HBV-related HCC cohort (Figure
1c). The downregulation of NFATc3 was further confirmed at
the protein level in five pairs of HBV-related HCC tissues
(Figure 1d). In line with the survival data from TCGA, patients
with lower NFATc3 mRNA expression had significantly lower
5-years OS rate (P= .021) than those with higher NFATc3
expression (Figure 1e) in our HBV-related HCC cohort.
Moreover, we investigated the correlations between the expres-
ssion status of NFATc3 and clinical parameters including tumor
size, tumor number, TNM stage and BCLC stage, but no
significant correlation was found (Table S2). We also analyzed
the expression and clinical significance of NFATc1, NFATc2
and NFATc4 in TCGA database. However, no survival prog-
nosis associations between these genes expression and HCC
patients were observed (Supplementary Figure 1a). These
results indicated that NFATc3 expression was downregulated
in HCC and might be related to the development and progression of HCC.

Next, we analyzed the potential mechanism for the downregulation of NFATc3 expression in HCC. Based on the TCGA-HCC database, we analyzed the copy number alterations (CNAs) of NFATc3 gene and found that NFATc3 gene was deleted in 44% (152/343) HCC tissues, which was the highest deletion rate among NFAT family genes (Figure 1f). In consistent with this result, our previous array-based comparative genomic hybridization (aCGH) data of 25 HBV-related HCC tissues showed that NFATc3 gene also had the highest deletion rate (24%, 6/25) (Figure 1g).

Figure 1. NFATc3 expression is downregulated in HCC tissues due to gene copy deletion. (a) NFATc3 mRNA levels in tumor (n = 372) and non-tumor (n = 50) tissues in TCGA-HCC database. (b) The association of NFATc3 expression status in tumor tissues and the prognosis of HCC patients (n = 364) in TCGA database. (c) NFATc3 mRNA levels in normal hepatic tissues (n = 7), paired para-tumor (n = 75) and tumor (n = 75) tissues of HBV-related HCC in our cohort, measured by qRT-PCR. (d) NFATc3 protein expression level in tumor (T, n = 5) and paired para-tumor (PT, n = 5) tissues of HBV-HCC patients in our cohort, examined by western blot. (e) The association of NFATc3 expression in tumor tissues and the prognosis of HCC patients (n = 60) in our HBV-related HCC cohort. (f, g) The copy number alterations (CNAs) of NFAT family genes in tumor tissues (n = 372) in TCGA-HCC database (f) and in HBV-related HCC tissues (n = 25) revealed by aCGH analysis (g). (h) NFATc3 mRNA expression in tumor tissues of NFATc3 copy neutral (0), heterozygous deletion (−1) and duplication (1/2) groups in TCGA-HCC database. (i) NFATc3 gene CNAs in HCC tissues caused by HBV, HCV and non-virus pathogenies. (a, c, h) Data were presented as the mean ± SD, P value was calculated by performing un-paired Student’s t-test, ***, P < .001; ****, P < .0001; ns, not significant. (b and e) Survival was calculated using Kaplan-Meier’s method and compared using log-rank test. (d) Data were representative of three experiments.
corresponding mRNA expression level of NFATc3 in gene copy deleted HCC tissues was significantly lower than that in neutral tissues (Figure 1b), while the expression level of NFATc1, NFATc2 and NFATc4 had no difference between these two groups (Supplementary Figure 1b). Furthermore, we analyzed the CNAs of NFATc3 gene in HCC with different etiology including HBV, HCV and non-virus infection in TCGA database. The results showed that NFATc3 gene deletion occurred in all three kinds of HCC, while the deletion frequency in HBV-HCC group (51%) was the highest (Figure 1i). Consistently, the NFATc3 mRNA expression was also downregulated in the deletion group of HBV-HCC tissues (Supplementary Figure 1c). To explore other causes of NFATc3 downregulation, the methylation status of NFATc3 CpG island site in non-tumor and tumor tissues was also compared. However, no significant difference of NFATc3 gene methylation between tumor and non-tumor tissues in TCGA database (Supplementary Figure 1d) or in paired tumor and para-tumor tissues derived from HBV-related HCC patients was observed (Supplementary Figure 1e), indicating the downregulation of NFATc3 expression was not caused by methylation modification. We also analyzed the NFATc3 gene mutation profile in TCGA-HCC database and found that there were five tumor samples with NFATc3 gene missense mutations among 372 HCC samples. Taken together, these results indicated that NFATc3 expression was downregulated mainly due to gene deletion in HCC tumor tissues, especially in HBV-related HCC.

3.2. NFATc3 inhibits the proliferation and migration capabilities of hepatoma cells

To better understand the role of NFATc3 in HCC, we determined the effects of NFATc3 on proliferation and migration abilities of HCC cells by using gain- and loss-of-function experiments. According to endogenous NFATc3 protein expression levels (Supplementary Figure 2a), we constructed a stable NFATc3 knockdown (NFATc3-KO) SMMC7721 cell line by CRISPR-Cas9 gene-editing system (Supplementary Figure 2b), while overexpressed NFATc3 in SK-HeP1 and SNU449 cells (Supplementary Figure 2c). The cell viability assay revealed that overexpression of NFATc3 significantly inhibited the proliferation of SNU449 (Figure 2a) and SK-HeP1 (Figure 2b) cells from the third day after NFATc3 overexpression. Conversely, NFATc3 knockdown accelerated the proliferation of SMMC7721 cells (Figure 2c). To extend our understanding of NFATc3 on tumor development in vivo, we subcutaneously injected NFATc3-KO and WT SMMC7721 cells into 4-week-old nude mice. As expected, we observed that the volume curves indicated faster growth of tumors in NFATc3-KO cells (Figure 2d, left panel) and the tumors formed by NFATc3-KO cells (Figure 2d, right panel) exhibited larger sizes and weights (Supplementary Figure 2d), suggesting that NFATc3 knockout could promote the growth of hepatoma cells. Next, we performed wound healing and transwell assays to detect the effects of NFATc3 on cell migration ability. The results showed that NFATc3 overexpression significantly inhibited the migration (Figure 2e) and invasion (Figure 2g) capabilities of SK-HeP1 and SNU449 cells according to statistical results of scratch area change (Supplementary Figure 2e) and the number of cells invading through the membrane (Supplementary Figure 2g). In contrast, knockout of NFATc3 significantly facilitated the migration (Figure 2f) and invasion of SMMC7721 cells (Figure 2h) which had a smaller scratch area ratio (Supplementary Figure 2f) and more cells invading through the membrane (Supplementary Figure 2h). Taken together, these results indicated that NFATc3 might function as a suppressor gene by inhibiting the proliferation and migration abilities of hepatoma cells.

3.3. NFATc3 effectively decreases the replication of HBV

It is well known that HBV infection is a leading cause of HCC. However, it remains unclear whether NFATc3 could suppress liver cancer by inhibiting HBV replication. To investigate the role of NFATc3 on HBV replication, we detected the levels of HBV-indicated markers in NFATc3 overexpressing or knockout hepatoma cells. The results of qPCR, ELISA and RT-qPCR assays showed that ectopic NFATc3 expression significantly decreased the levels of HBV DNA, hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in culture supernatant, and 3.5 kb HBV RNA in cells, when we co-expressed NFATc3 and HBV replisome in Hep3B cells (Figure 3a). Consistently, the overexpression of NFATc3 led to the similar results in HepAD38 cells, a tetracycline inducible HBV expressing cell line (Figure 3b). In contrast, the levels of HBV-indicated markers were greatly elevated in NFATc3-KO SMMC7721 cells, as compared to WT cells (Figure 3c). Moreover, we confirmed that NFATc3 and 1.2x HBV plasmids co-delivered into mice by hydrodynamic injection significantly decreased both HBsAg and HBeAg levels in mice sera (Figure 3d). These results indicated that NFATc3 significantly inhibited HBV replication in hepatocytes.

Next, we analyzed the correlation between HBV DNA level and NFATc3 expression in HCC patients. Based on the data derived from our HBV-related HCC patient cohort, we found that patients with lower NFATc3 mRNA expression in para-tumor tissues had significantly higher serum HBV DNA levels (Figure 3e), supporting the potential anti-viral role of NFATc3 against HBV.

3.4. NFATc3 is critical for IFN responses in hepatocytes

According to the previous studies, NFATc3 could upregulate type I IFNs expression downstream the Toll-like receptor 7/9 in pDCs to inhibit virus replication. In nonimmune cells, RIG-I is an important pattern recognition receptor (PRR) to recognize viral RNA, and induce downstream IFN response. It has been reported that the RNA sensor RIG-I could recognize HBV derived pre-genomic RNA (pgRNA) to promote IFN-α production. Thus, to further explore the effect of NFATc3 on immune genes expression in hepatocytes, we performed next-generation RNA sequencing (RNA-Seq) in WT and NFATc3-KO SMMC7721 cells, with Sendai virus (SeV) infection which can activate innate immune through RIG-I pathway. Using RNA-seq approach, we first analyzed differentially expressed genes (DEGs, fold change > 2) between two groups (Figure 4a) and screened out innate immune-related
DEGs (Figure 4b). With further analysis of the RNA-seq results, we found that only the expression of IFNB1 in type I IFNs and type III IFNs (IFNL1, IFNL2 and IFNL3) could be detected in SMMC7721 cells, while IFNAs were below the detection limit. Compared to WT cells post infection, the expression of IFNL1 was significantly downregulated in NFATc3-KO SMMC7721 cells (-Log10 (P adjust) = 17, Log2 (fold change) = 2.21). However, the expression of IFNB1, IFNL2 and IFNL3 showed no significant difference between two groups of cells (Figure 4c). Besides IFNs, some ISGs were
Figure 3. NFATc3 effectively decreases HBV replication. (a, b) Transient co-transfected 1.2x HBV plasmid and NFATc3 plasmid or vector in Hep3B cell lines (a), transient transfected NFATc3 plasmid or vector in HepAD38 cells (tet-off, b), after 5 days and detect four HBV indicators, HBsAg, HBeAg, and HBV DNA in cultural supernatant, 3.5 kb HBV RNA in cell. (c) Transient co-transfected prcccDNA plus pCMV-Cre or pCMV-vector in WT & NFATc3-KO SMMC7721 cells for 5 days, detected HBV indicators. (d) In the C57BL/6 wide-type mouse model established by hydrodynamic tail vein injection of 1.2x HBV replication clone plasmid, together transfecting with human NFATc3 expressing or vector plasmids, and detected HBsAg and HBeAg levels in peripheral blood of the mice at 3, 5 and 7 days. (e) The peripheral blood HBV DNA levels between high (n=18) and low (n=18) NFATc3 expression groups (according expression median in para-tumor tissues) in our HBV-related HCC cohort. Data were presented as the mean ± SD, P value was calculated by performing un-paired Student’s t-test, *, P < .05; **, P < .01; ***, P < .001; ns, not significant.
also downregulated significantly in NFATc3-KO SMMC7721 cells (Figure 4d).

To confirm the effect of NFATc3 on IFNs and ISGs expression after SeV infection, we performed qRT-PCR to detect the mRNA expression levels of IFNL1, IFNB1, ISG15, ISG54 and RIG-I, which are important and highly induced immune genes in hepatocytes.\(^{35-37}\) The results showed that mRNA levels of IFNL1, IFNB1, ISG15, ISG54 and RIG-I were significantly lower in NFATc3-KO SMMC7721 cells than that in WT cells post SeV infection (Figure 4e). And consisted of the mRNA level, the protein level of RIG-I was also downregulated in NFATc3-KO SMMC7721 cells after SeV infection (Figure 4f). Conversely, overexpression of NFATc3 in HEK293T cells increased the mRNA level of these genes (Figure 4g) and the protein level of RIG-I (Figure 4h) after SeV infection. Taken together, these results suggested that NFATc3 could specifically upregulate IFNL1 and IFNB1 expression and activate downstream ISGs in hepatocytes. Since the endogenous expression level of IFNAs was too low in hepatoma cells and knockout of NFATc3 did not affect the expression of IFNL2 and IFNL3 genes, we did not analyze these IFNs in this study.

3.5. NFATc3 induces the transcription of IFNs by binding to their promoters

It has been reported that NFATc3 can bind to the consensus sequence (T/AGGAAA) within the promoter regions of the target genes.\(^{38}\) We analyzed the sequences in the promoter regions of IFNL1 and IFNB1 genes and found that both
promoters contained potential NFATc3 binding sites. To explore whether NFATc3 regulates the transcription of IFNB1 and IFNL1 genes in hepatocytes, we constructed luciferase reporter plasmids containing the promoter regions of IFNL1 and IFNB1 genes with wild-type or mutant (TGAGAAA to T/AACCTTT) NFATc3 binding sites (Figure 5a). By using dual luciferase reporter system, we demonstrated that NFATc3 increased the transcriptional activities of wild-type promoters of IFNL1 and IFNB1 in HEK293T and hepatoma cell lines including SK-Hep1, SNU449, and Hep3B respectively, and this effect was attenuated or even abolished when NFATc3 binding site was mutated (Figure 5b,c). In addition, the luciferase activity of both wild-type IFNB1 and IFNL1 promoter was increased by NFATc3 in a dose-dependent manner, while mutant IFNB1 and IFNL1 promoters were not affected by NFATc3 (Supplementary Figure 3a, b). Further ChIP-PCR assay confirmed that NFATc3 could bind to the targeted DNA fragments in IFNB1 and IFNL1 promoters (Figure 5d). Meanwhile, we observed that the interferon-stimulated response element (ISRE) activities were also activated by ectopic NFATc3 expression in HEK293T and hepatoma cell lines including Hep3B, SNU449, and SK-Hep1 (Supplementary Figure 3c). Consistent with this result, treated with culture supernatants from all four cells with ectopic NFATc3 expression could significantly increase luciferase activities in 2TGH-ISRE cells (Supplementary Figure 3d), supporting the induction of IFNs in those NFATc3 overexpressing cells.

Next, we confirmed that the mRNA levels of IFNL1, IFNB1, ISG15 and ISG54 were significantly upregulated in hepatoma cell lines (Figure 5g) with overexpression of NFATc3. Similar results were observed in HEK293T cells (Supplementary Figure 3e). Importantly, transient transfection of NFATc3 plasmid in NFATc3-KO SMMC7721 cells could rescue the expression of IFNL1, IFNB1, ISG15 and ISG54 (Figure 5h). As for RIG-I, which could inhibit HCC carcinogenesis and predict HCC patient prognosis, 39,40 a positive correlation was found between RIG-I and NFATc3 mRNA expression in TCGA-HCC database (Figure 5e), and RIG-I protein level was increased after NFATc3 overexpressing in HEK293T and Hep3B cells (Figure 5f). Furthermore, we confirmed that the mRNA level of NFATc3 was positively correlated with that of IFNL1 (Figure 5i) and IFNB1 (Figure 5i) in para-tumor tissues from HBV-related HCC patients. And in HBV-infected liver tissues from GSE83148 database, positive correlations between NFATc3 and IFNL1/IFNB1 expression also existed (Supplementary Figure 3f, g). The above results indicated that NFATc3 could bind to the promoter regions of IFNL1 and IFNB1, and promote their transcription and downstream ISGs expression in hepatocytes.

3.6. IFNs pathway mediates the anti-HCC and anti-HBV functions of NFATc3 in hepatocytes

The IFNs are important immune cytokines which have been used for treatment of hepatitis B and HCC. To further confirm whether NFATc3 exerts anti-HCC and anti-HBV function through upregulating IFNs in hepatocytes, we treated NFATc3 overexpressed SK-Hep1, SNU449 and HepAD38 cells by using recombinant orthopoxviral immunomodulatory proteins (B18R), an IFN receptors antagonist, to block type I and type III IFN pathways.41,42 We found that the inhibitory effects of NFATc3 on the cell proliferation were reversed in SK-Hep1 and SNU449 cells (Figure 6a,b). Similarly, B18R treatment significantly attenuated the inhibitory effects of NFATc3 on HBV replication (Figure 6c). These results suggested that NFATc3 plays important anti-HCC and anti-HBV roles in an IFN-dependent manner in hepatocytes.

3.7. NFATc3 enhances RIG-I/MAVS/IRF7-mediated IFN response

The downstream signaling mediated by RIG-I requires the protein adaptor MAVS, which coordinates the activation of IRF3 and IRF7 and thereby inducing IFNs expression.32 To investigate whether NFATc3 is involved in RIG-I pathway-mediated IFNs induction, we performed a series of experiments by using NFATc3 overexpressing and knockout cells. First, we detected the transcriptional activities of wild-type IFNL1 and IFNB1 promoters after co-expressing NFATc3 with MAVS, IRF7 and IRF3 respectively in HEK293T cells. The results showed that overexpression of any of these proteins could upregulate the promoter activities of wild-type IFNL1 and IFNB1, while NFATc3 exhibited significantly stronger synergistic effects on IFN promoters only when co-expressing with MAVS (Figure 7a) or IRF7 (Figure 7b). However, no such synergistic effect on mutant IFNL1 promoter was observed (Supplementary Figure 4a). Such upregulating effects of NFATc3 on IFNB1 and IFNL1 promoters exhibited a dose-dependent manner with MAVS (Supplementary Figure 4b) or IRF7 co-expression (Supplementary Figure 4c). Secondly, we tested the expression of IFNL1 and IFNB1 after co-expressing NFATc3 with MAVS and IRF7, respectively. The synergistic effects between NFATc3 and MAVS or IRF7 on upregulating the expression of IFNs (Figure 7c) and downstream ISGs (Figure 7d) were also confirmed in HEK293T cells. These results were further supported in WT and NFATc3-KO SMMC7721 cells. As shown in Figure 7 e, knockout of NFATc3 significantly weakened the promoter activities of IFNL1 and IFNB1 after MAVS or IRF7 overexpression. Consistently, NFATc3 knockout significantly inhibited MAVS- or IRF7-induced IFN response in SMMC7721 cells (Figure 7g). Next, the transcriptional activities of IFNL1 and IFNB1 promoters were detected in HEK293T cells with NFATc3 overexpression and in SMMC7721 cells with NFATc3 knockout after SeV infection. The synergistic effects between NFATc3 and MAVS or IRF7 on upregulating the transcription activities of wild-type IFNL1 and IFNB1 promoters were also observed in HEK293T (Figure 7h) and SMMC7721 cells (Figure 7i). And the upregulating effect of NFATc3 on IFNL1 promoter activity after RIG-I activation was not observed when NFATc3 binding site was mutated in HEK293T cells (Supplementary Figure 4d). These findings indicated that NFATc3 might be involved in RIG-I/MAVS/IRF7-mediated IFN response in hepatocytes.
Figure 5. NFATc3 induces the transcription of IFNs by binding to their promoters. (a) Diagram for wide-type and mutant binding sites of NFATc3 on IFNL1 and IFNB1 promoters. (b, c) Transfected with plasmid encoding NFATc3 or empty vector in HEK293T and hepatoma cell lines for 36 hours, detected luciferase activities of NFATc3 wide-type and binding site-mutant IFNL1 (b) and IFNB1 (c) promoters. (d) ChIP and semi-quantitative PCR were used to detect interactions between NFATc3 to IFNL1 and IFNB1 promoters after over-expressing NFATc3 with flag-tag in HEK293T cells for 48 hours, integrated optical density of each band was measured and analyzed. (e, f) qRT-PCR analysis of IFNs and ISGs expression in SNU449, Sk-Hep1, Hep3B (e) and NFATc3-KO SMMC7721 (f) cells with or without NFATc3 expression plasmid transfected for 48 hours. (g) Expression correlation between NFATc3 and RIG-I gene in liver tissues in TCGA database. (h) Protein levels of NFATc3 and RIG-I in 293 T and Hep3B cells after over-expressed NFATc3 for 48 hours. (i, j) Analysis of expression correlations between NFATc3 and IFNL1 (i, n = 36) or IFNB1 (j, n = 18) in para-tumor tissues of HBV-related HCC patients in our cohort. (b, c, e-p) Data were presented as the mean ± SD, P value was calculated by performing un-paired Student’s t-test, *P < .05, **P < .01, ***P < .001; ns, not significant. (g, i, j) Spearman rank correlation test was used to calculate a correlation between two nonparametric values. (d, h) Data were representative of three experiments.
3.8. RIG-I/MAVS/IRF7 pathway upregulates NFATc3 expression and promotes its nuclear localization

The expression status of NFAT proteins and their translocation from the cytoplasm to the nucleus are critical for activating the transcription of downstream target genes. Thus, we investigated whether the activation of RIG-I/MAVS/IRF7 pathway could regulate the expression and localization of NFATc3. The qRT-PCR and western blot assays identified a significant upregulation of NFATc3 mRNA and protein level in both SMMC7721 (Figure 8a) and Huh7 cells infected with SeV (Figure 8c). In addition, the nuclear localized NFATc3 protein was significantly increased both in SMMC7721 (Figure 8b) and Huh7 cells (Figure 8d). In consistent with the above results, overexpression of either MAVS or IRF7 also increased endogenous expression and nuclear localization of NFATc3 in SMMC7721 (Figure 8e,f) and Huh7 cells (Figure 8g,h). Furthermore, in GSE83148 database, NFATc3 mRNA level was positively correlated with MAVS and IRF7 mRNA levels in liver tissues (Supplementary Figure 5a, b). Taken together, the above results suggested that RIG-I/MAVS/IRF7 pathway might mediate NFATc3 activation through upregulating its expression and promoting its nuclear localization.

To further explore the relationship between NFATc3 and RIG-I pathway in HCC, we analyzed our aCGH data and TCGA-HCC database. The results showed that besides NFATc3, high deletion frequencies of RIG-I, MAVS and
NFATc3 enhances RIG-I/MAVS/IRF7-mediated IFN response. (a,b) Luciferase activities of wild-type IFNL1 (a) and IFNB1 (b) promoters in HEK-293 T cells co-transfected plasmids encoding MAVS, IRF7 and IRF3 with NFATc3 or empty vector for 36 hours. (c,d) qRT-PCR analysis of IFNs (c) and ISGs (d) mRNA expression in HEK293T cells transfected with plasmids encoding MAVS or IRF7 together with NFATc3 or empty vector for 48 hours. (e) Luciferase activities of IFNL1 and IFNB1 promoters were detected after transfection of plasmids encoding MAVS or IRF7 in WT and NFATc3-KO SMMC7721 cells for 48 hours. (f,g) IFNs (f) and ISGs (g) mRNA levels detected after overexpression of MAVS or IRF7 in WT and SMMC7721-KO cells. (h) Luciferase activities of IFNL1 and IFNB1 promoters were measured in vector control and NFATc3 overexpressing HEK293T cells infected with SeV for 24 hours. (i) Luciferase activities of IFNL1 and IFNB1 promoters were measured in WT/NFATc3-KO SMMC772 cells infected with SeV for 24 hours. Data were presented as the mean ± SD, P value was calculated by performing un-paired Student’s t-test, *, P < .05; **, P < .01; ***, P < .001; ns, not significant.
IRF7 were also found in HCC tumor tissues. More than half of the tumor tissues had at least one of these genes deleted in our cohort (Supplementary Figure 5c) and data from TCGA-HCC database (Supplementary Figure 5d). Similar to NFATc3, downregulated expression of RIG-I and IRF7 was also observed in gene copy deleted groups compared to neutral
groups in HCC tumor tissues (Supplementary Figure 5e). The mRNA levels of these two genes were also lower in HCC tumor tissues compared with non-tumor samples (Supplementary Figure 5f). Taken together, these results indicated that the disability of innate immunity due to NFATc3/RIG-I/MAVS/IRF7 axis inactivation plays an important role in hepatocarcinogenesis.

4. Discussion

NFAT proteins were firstly described almost three decades ago. Since then, the physiological functions of different NFAT homologues in the immune system and many other tissues have been uncovered. However, the role of individual NFAT members in the context of tumorigenesis and virus infection in hepatocytes remains unrevealed. We reported here for the first time that NFATc3 gene was frequently deleted and caused its downregulated expression in HCC, and propose the possibility that NFATc3 might function as a tumor suppressor by activating anti-tumor and anti-virus immune responses in hepatocytes. Mechanistically, NFATc3 functions as a downstream transcription factor of RIG-I-MAVS-IRF7 pathway to upregulate IFNL1 and IFNB1 expression in hepatocytes.

The involvement of NFAT proteins in carcinogenesis and immunity has been reported.44 In this study, the downregulation of NFATc3 was found mainly caused by gene copy deletion in HCC tumor tissues, and more importantly, lower NFATc3 expression was associated with poor prognosis of HCC patients. More than that, NFATc3 inhibited the proliferation and migration capabilities of hepatoma cells, suggested a potential tumor suppressor role of NFATc3 in HCC. In addition, NFATc3 inhibited HBV replication in both in vitro and in vivo HBV replication systems. In line with this, negative correlation was found between NFATc3 mRNA level and serum HBV viral load in HBV-related HCC patients. Thus, we conclude that NFATc3 is able to suppress HCC by inhibiting cell proliferation and migration, as well as HBV replication since HBV is a carcinogenic virus.45 However, further studies are needed to confirm the interference between NFATc3 and HBV replication in HBV model systems that recapitulate natural infection process.

As transcription factors, NFAT proteins induce the expression of cytokines including IL-2, IL-3, IL-4, and IL-5.46 It has been postulated that NFATs are not involved in IFNs production based on evolutionary analysis.47 However, a recent study has demonstrated that NFATc3 is a unique member of the NFAT family that plays a critical role in regulating type I IFNs production in pDCs.16 In this study, we analyzed the sequences of all type I and type III IFN promoters and found that NFAT binding site (T/AGGAAA) exists within the promoters of all type I IFNs, as well as IFNL1, but not IFNLC2 or IFNL3. Since among all type I IFNs, only the expression of IFNB1 could be detected in SMMC7721 cells in our RNA-seq data, we focused on the regulatory effect of NFATc3 on IFNB1 and IFNL1 in our further study. By using ChIP-PCR, qRT-PCR and luciferase assays, we demonstrated that NFATc3 could bind to the promoter regions of both IFNB1 and IFNL1 and transcriptionally activate the expression of IFNs. Also, NFATc3 could activate ISGs expression by upregulating IFNs expression. Furthermore, we confirmed that the IFNs receptor antagonist could attenuate the inhibitory effects of NFATc3 on both HCC cell proliferation and HBV replication. Thus, we conclude that NFATc3 plays important anti-HCC and anti-HBV roles in an IFN-dependent manner in hepatocytes.

As for the RIG-I pathway, RIG-I first recognizes exogenous RNA, then the adaptor MAVS forms prion-like aggregates on the mitochondria to recruit downstream kinases and thereby phosphorylates IRF7 to regulate IFNs and ISGs expression.45,48 In HBV-infected hepatocytes, RIG-I recognizes HBV pgRNA and induces IFN-λ expression.49 In this study, we found that NFATc3 participated in the RIG-I pathway to enhance type I and type III IFN responses in hepatocytes. On the one hand, NFATc3 could enhance the upregulating effect of RIG-I pathway on IFNL1 and IFNB1 promoter activities via synergizing with MAVS and IRF7, which was further confirmed by their synergistic effects on upregulating the expression of IFNs and ISGs. On the other hand, RIG-I pathway activation and overexpression of MAVS or IRF7 could upregulate NFATc3 expression at both mRNA and protein levels, and promote NFATc3 protein translocating into cell nucleus. These results revealed a previously unknown aspect of NFATc3 that functions as a novel positive feedback regulator of RIG-I pathway in hepatocytes. However, the detailed mechanism of this regulation between NFATc3 and RIG-I pathway remains to be further investigated.

Meanwhile, it has been reported that NFATc3 could interact with IRF7 to promote its nuclear localization,16 and we also found that IRF7 conserved recognition sequences (GAAA)49 existed on the promoter of NFATc3 gene. In addition, we noticed a smaller band of NFATc3 protein detected by western blot in hepatoma cell nucleus after SeV stimulation or MAVS and IRF7 overexpression. Since NFAT protein is usually activated upon dephosphorylation by calcineurin, afterward translocating into nucleus,50 the band of NFATc3 with lower molecular weight implicated the dephosphorylation and activated status of NFATc3 protein in the nucleus (Figure 8). So, the possible regulation mechanism of RIG-I pathway on NFATc3 is that, after RIG-I activation, the phosphorylated IRF7 interacts with NFATc3 to form an IRF7/NFATc3 complex and promotes NFATc3 nuclear localization, while in the nucleus, IRF7 further functions as a transcription factor binding to NFATc3 promoter and upregulating its expression. Further studies are needed to explore the effects and detailed mechanism of RIG-I pathway on NFATc3 protein activation.

In summary, this study demonstrates that NFATc3 directly binds to the promoter regions of IFNL1 and IFNB1 to activate their transcription in a synergized manner with RIG-I pathway, and plays a crucial role in inhibiting HBV replication and HCC tumorigenesis in hepatocytes. During multiple steps of hepatocyte carcinogenesis, deletion of NFATc3 and other genes of RIG-I pathway might facilitate viral replication and eventually promote tumorigenesis. These results provide new insights into the complex molecular regulatory mechanisms of RIG-I/NFATc3/IFNs axis during HBV-related HCC carcinogenesis.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.
Funding

This work was supported by the Beijing Natural Science Foundation (Nos. 7182079, 7182080), the Natural Science Foundation of China (Nos. 81572366, 81672741), and the National S & T Major Project for Infectious Diseases of China (Nos. 2017ZX10022203, 2017ZX10022202 and 2017ZX10021012).

ORCID

Fengmin Lu http://orcid.org/0000-0002-1832-3209

Author's contributions

Xiaobin Zao and Jin Cheng: acquisition of data, analysis and interpretation of data, drafting of the manuscript, statistical analysis; Xiaoyu Feng, Deyao Li and Tianxu Liu: acquisition of data; Guiven Guan, Jun Zou and Jing Zhang: statistical analysis; Congle Shen and Ting Zhang: support of experimental technology; Jie Wang and Jia Liu: administrative, technical, or material support; Fuping Yuan: material support, study supervision, critical revision of the manuscript for important intellectual content. Xiangmei Chen and Fengmin Lu: study concept and design, obtained funding, study supervision, critical revision of the manuscript for important intellectual content. All authors of this research have approved the final version of the article.

Abbreviations

HBV Hepatitis B virus
HCC Hepatocellular Carcinoma;
IFNs Interferons
IFNβ Interferon Beta 1
IFNλ1 Interferon Lambda 1
ISGs Interferon-Stimulated Genes
ISRE Interferon-Stimulated Response Element
TCGA The Cancer Genome Atlas
GEO Gene Expression Omnibus
NFATc3 Nuclear Factor of Activated T cells 3
RNA-seq RNA-sequencing
RIG-I Retinoic Acid-Inducible Gene I
pgRNA pre-genomic RNA
MAYS Mitochondrial Antiviral Signaling Protein
TLR Toll-Like Receptor
IRF Interferon Regulate Factor
IL-2 Interleukin-2
pDCs plasmacytoid Dendritic Cells
CNAs Copy Number Alterations
OS Overall Survival
MSRE-qPCR Methylation Specific Restrictive Enzyme based quantitative PCR
ChIP Chromatin Immunoprecipitation
SeV Sendai virus
qPCR quantitative polymerase chain reaction
qRT-PCR Quantitative reverse transcription PCR
HBsAg Hepatitis B surface Antigen
HBsAg Hepatitis B e Antigen
NFATc3-WT NFATc3 gene Wild Type
NFATc3-KO NFATc3 gene Knock Out.

References

1. Chan HL, Sung JI. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26(2):153–161. doi:10.1055/s-2006-939753.
2. W.H. Organization. Global hepatitis report, 2017. 2017.
3. Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin liver Dis, 39 (2019) 26–42.
4. Qin J-J, Nag S, Wang W, Zhou J, Zhang W-D, Wang H, Zhang R. NFAT as cancer target: mission possible? Biochim Biophys Acta. 2014;1846(2):297–311. doi:10.1016/j.bbaglyc.2014.07.009.
5. Serrano-Perez MC, Fernandez M, Neria F, Berjon-Otero M, Doncel-Perez E, Cano E, Tranque P. NFAT transcription factors regulate survival, proliferation, migration, and differentiation of neural precursor cells. Glia. 2015;63(6):987–1004. doi:10.1002/glia.22797.
6. Pan MG, Xiong Y, Chen F. NFAT gene family in inflammation and cancer. Curr Mol Med. 2013;13(4):543–554. doi:10.2174/1566524011313040007.
7. Glad SZ, Sorensen AB, Andrulis M, Wang B, Kondo E, Jussen R, Krenacs L, Stelkovics E, Wabl M, Serfling E, et al. A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus. Blood. 2005;106(10):3546–3552. doi:10.1182/blood-2005-02-0493.
8. Lee H, Chouinard L, Bonin M, Michel RN. NFATc3 deficiency may contribute to the development of mammary gland adenocarcinoma in aging female mice. Mol Carcinog. 2005;44(3):219–222. doi:10.1002/mc.20136.
9. Lee SH, Kieu C, Martin CE, Han J, Chen W, Kim JS, Kang MK, Kim RH, Park N-H, Kim Y, et al. NFATc3 plays an oncogenic role in oral/oropharyngeal squamous cell carcinomas by promoting cancer stemness via expression of OCT4. Oncotarget. 2019;10(23):2306–2319. doi:10.18632/oncotarget.26777.
10. Lee SH, Rigas NK, Lee CR, Bang A, Srikantan S, Gwack Y, Kang MK, Kim KH, Park NH, Shin KH. Oral1 promotes tumor progression by enhancing cancer stemness via NFAT signaling in oral/oropharyngeal squamous cell carcinoma. Oncotarget. 2016 Jul 12; (28):43239–43255. doi:10.18632/oncotarget.9755.
11. Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014;25 (4):369–376. doi:10.1016/j.cytogfr.2014.07.015.
12. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 2000;118(2):S83–103. doi:10.1016/s0016-5085(00)70008-4.
13. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthney JN, Curley SA, Ellis LM. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2005;23(3):421–427. doi:10.1200/JCO.2003.10.103.
14. Zanoni I, Granucci F, Broggi A. Interferon (IFN)-lambda takes the helm: immunomodulatory roles of type III IFNs. Front Immunol. 2017;8:1661.
15. Tian S, Hui X, Fan Z, Li Q, Zhang J, Yang X, Ma X, Huang B, Chen D, Chen H. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-α1 or PEG-interferon-α1. FASEB J... 2014;28(8):3528–3539. doi:10.1096/fj.14-250704.
16. Bao M, Wang Y, Liu Y, Shi P, Lu H, Sha W, Weng L, Hanabuchi S, Qin J, Plumas J, et al. NFATC3 promotes IRF7 transcriptional activity in placmytoid dendritic cells. J Exp Med. 2016;213 (11):2383–2398. doi:10.1084/jem.20160438.
17. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680–692. doi:10.1016/j.immuni.2011.10.003.
18. Koch A, Jeschke J, Van Criekinge W, van Engeland M, De Meyer T. MEXPRESS update. Nucleic Acids Res. 2019;47(W1):W561–W565. doi:10.1093/nar/gkz445.
19. Gao J, Aksoy BA, Dogrusoz U, Dresdnher G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013;6(269). doi:10.1126/scisignal.2004088.
20. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095.
